<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109949</url>
  </required_header>
  <id_info>
    <org_study_id>CUCS-INTEC-XOLOTL</org_study_id>
    <nct_id>NCT05109949</nct_id>
  </id_info>
  <brief_title>Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes</brief_title>
  <official_title>Acute Effect of Empagliflozin vs Dapagliflozin vs Placebo Administration Over Pulse Wave Velocity in Patients With Type Two Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitario de Ciencias de la Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Universitario de Ciencias de la Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date one of the main independent biomarkers of cardiovascular disease is the arterial&#xD;
      stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2&#xD;
      inhibitors develop cardiac protection over long term administration, but there's not enough&#xD;
      studies about acute effects in early administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Measure basal carotid-femoral Pulse Wave Velocity through a Pulse Pen tonometer by DiaTecne&#xD;
      among basic physical examination, blood test, anthropometric and hemodynamic measurements;&#xD;
      then administrate randomly dapagliflozin 10 mg, empagliflozin 25 mg or placebo for 7 days and&#xD;
      then perform all of the measurements and blood test again.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline carotid-femoral pulse wave velocity at 7 days. Using a PulsePen tonometer by DiaTechne.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using the BioSystems® Glucose Oxidase / Peroxidase kit; in an automated clinical chemistry analysis equipment brand XL-100Erba</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using the BioSystems® Glucose Oxidase / Peroxidase kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using the BioSystems® Glycerol phosphate Oxidase / Peroxidase kit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using the BioSystems® Direct / Detergent HDL kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein cholesterol</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using the BioSystems® Cholesterol Oxidase / Peroxidase kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using the BioSystems® kit Modified Jaffe's no deproteinization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>7 days</time_frame>
    <description>Change from baseline, using an OMRON calibrated electronic digital sphygmomanometer model HEM 907 XL. The patient will remain seated in a chair resting his back on the backrest, with a minimum rest of 5 minutes, The average of 3 measurements such as BP will be taken</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Diabetes Mellitus Type 2 Without Complication</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to a sodium-glucose cotransporter 2 (SGLT2) inhibitors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin is an oral medication used to treat Type 2 diabetes. It belongs to sodium-glucose cotransporter 2 (SGLT2) inhibitors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcinated magnesium is a white powdery compound, MgO, used in pharmaceuticals as binder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10Mg Tab</intervention_name>
    <description>Daily morning dose per oral of Dapagliflozin 10 mg for 7 days</description>
    <arm_group_label>Dapagliflozin 10 mg</arm_group_label>
    <other_name>Farxiga, Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>Daily morning dose per oral of Empagliflozine 25 mg for 7 days</description>
    <arm_group_label>Empagliflozin 25 mg</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily morning dose per oral of Calcined magnesite 500 mg for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of T2DM&#xD;
&#xD;
          -  HbA1c &gt; 7 y &lt; 10&#xD;
&#xD;
          -  BMI 25 - 34.9 kg/m2&#xD;
&#xD;
          -  Signature of consent under information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Treated with insulin and / or loop diuretics and thiazides&#xD;
&#xD;
          -  T1DM&#xD;
&#xD;
          -  Hypotension&#xD;
&#xD;
          -  Any autoimmune disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Women whitout birth control method&#xD;
&#xD;
          -  Women taking oral birth control or under hormone replacement therapy&#xD;
&#xD;
          -  Woman pregnant or breastfeeding&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  Patients with a cardiovascular disease that contraindicates the use of this&#xD;
             pharmacological class&#xD;
&#xD;
          -  Glomerular filtration rate &lt;60ml/min (Cockcroft-Gault)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Grover-Páez, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Universitario de Ciencias de la Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Grover Paez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

